Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

In a phase 2 randomized placebo-controlled trial, Neil Formica and coauthors investigate the immunogenicity and safety of different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine in younger and older adults in USA and Australia.

Related Keywords

United Kingdom ,United States ,Australia ,New Zealand ,Texas ,South Africa ,Maryland ,Melbourne ,Victoria ,Baylor College Of Medicine ,Mark Adams ,Terry Klein ,Fiona Napier ,Paul Griffin ,Jason Lickliter ,Mark Arya ,Cheryl Keech ,Amber Leah ,Paul Nugent ,Susan Thackwray ,Novavax Gaithersburg ,Ira Berger ,Mark Turner ,Joshua Kim ,Astrazeneca Oxford ,Charlotte Lemech ,Paul Bradley ,Mary Beth Manning ,Maheshin Ramasamy ,University Of Oxford ,International Conference On Harmonisation ,Department Of Defense ,Study Group ,Drug Administration ,Melinda Gates Foundation ,Coalition Of Epidemic Preparedness Innovations ,Coalition For Epidemic Preparedness Innovations ,Phase Five Communications ,Alfred Hospital Human Research Ethics Committee Melbourne ,Baylor College Of Medicine Houston ,Pearson ,Novavax Inc ,Creative Commons Attribution License ,Supporting Information ,Epidemic Preparedness Innovations ,Operation Warp Speed ,Epidemic Preparedness ,Alfred Hospital Human Research Ethics Committee ,Advarra Central Institutional Review Board ,International Conference ,Good Clinical Practice ,Medical Dictionary ,Regulatory Activities ,Baylor College ,Analysis Sets ,Per Protocol Analysis Set ,Safety Analysis Set ,Eugene Athan ,Richard Glover ,Scott Kitchener ,Fiona Napier Flood ,Vaccination And Immunization ,Sars Cov 2 ,Antibodies ,Vaccines ,Enzyme Linked Immunoassays ,Age Groups ,Antibody Response ,Antigens ,